GlassScriptPhysician profile
Ronald E Hoenzsch
NPI 1629060736
$7,374.98
in general payments reported to CMS, 2019-2025
49 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $952 · 2021: $1,420 · 2022: $1,066 · 2023: $1,077 · 2024: $979 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,389.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,388.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,452.84 | 2020-2025 | |
| Glaxosmithkline, LLC. | $840.41 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $789.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $424.23 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.42 | 2019-2025 | Jardiance |
| Pfizer INC. | $302.77 | 2019-2025 | |
| Abbott Laboratories | $259.83 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $236.77 | 2020-2025 | Zepbound, Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.52 | 2020-2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $204.23 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Janssen Pharmaceuticals, INC | $181.93 | 2019-2022 | |
| Allergan, INC. | $138.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $134.48 | 2019-2023 | Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $134.12 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $121.05 | 2019-2025 | Eliquis |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $113.43 | 2019-2021 | |
| Amarin Pharma, INC. | $90.92 | 2019-2021 | |
| Astellas Pharma US INC | $87.04 | 2022-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $75.18 | 2019-2021 | |
| Eisai INC. | $75.06 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $74.25 | 2023-2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $73.62 | 2019-2023 | Livalo, Seglentis |
| Bayer Healthcare Pharmaceuticals INC. | $72.79 | 2021-2023 | |
| Amneal Pharmaceuticals LLC | $69.58 | 2019-2023 | Unithroid |
| Sanofi Pasteur INC. | $68.40 | 2019-2025 | |
| Exact Sciences Corporation | $64.93 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $62.22 | 2023 | Gemtesa |
| Phathom Pharmaceuticals, INC. | $61.11 | 2025 | Voquezna |
| Dexcom, INC. | $59.48 | 2024-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $57.06 | 2024 | Rexulti |
| Currax Pharmaceuticals LLC | $56.38 | 2020-2022 | |
| Renalytix Ai, INC. | $48.46 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Sunovion Pharmaceuticals INC. | $36.56 | 2022 | |
| Ibsa Pharma INC. | $31.74 | 2021-2025 | Tirosint, Licart, Flector |
| Sanofi-Aventis U.S. LLC | $30.07 | 2020 | |
| Axsome Therapeutics, INC. | $27.77 | 2024 | Auvelity |
| Avion Pharmaceuticals | $27.66 | 2020 | |
| Xeris Pharmaceuticals, INC. | $27.41 | 2023 | Gvoke Hypopen |
| Vertex Pharmaceuticals Incorporated | $25.28 | 2025 | |
| Almatica Pharma LLC | $19.81 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.69 | 2019 | |
| Seqirus USA INC | $19.28 | 2024 | Fluad, Flucelvax |
| Ironwood Pharmaceuticals, INC | $19.22 | 2020 | |
| Mylan Specialty L.P. | $17.90 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.31 | 2021 | |
| Biogen, INC. | $16.94 | 2025 | Skyclarys |
| Esperion Therapeutics, INC. | $16.74 | 2025 | Nexletol |
| Dermira, INC. | $15.00 | 2020 | |
| Kaleo, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Hoenzsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.